Abstract:Background: Our study aimed to describe the group of severe COVID-19 patients at an institutional level, and determine factors associated with different outcomes. Methods: A retrospective chart review of patients admitted with severe acute hypoxic respiratory failure due to COVID-19 infection. Based on outcomes, we categorized 3 groups of severe COVID-19: (1) Favorable outcome: progressive care unit admission and discharge (2) Intermediate outcome: ICU care (3) Poor outcome: in-hospital mortality. Results: Eighty-nine patients met our inclusion criteria; 42.7% were female. The average age was 59.7 (standard deviation (SD):13.7). Most of the population were Caucasian (95.5%) and non-Hispanic (91.0%). Age, sex, race, and ethnicity were similar between outcome groups. Medicare and Medicaid patients accounted for 62.9%. The average BMI was 33.5 (SD:8.2). Moderate comorbidity was observed, with an average Charlson Comorbidity index (CCI) of 3.8 (SD:2.6). There were no differences in the average CCI between groups(p = 0.291). Many patients (67.4%) had hypertension, diabetes (42.7%) and chronic lung disease (32.6%). A statistical difference was found when chronic lung disease was evaluated; p = 0.002. The prevalence of chronic lung disease was 19.6%, 27.8%, and 40% in the favorable, intermediate, and poor outcome groups, respectively. Smoking history was associated with poor outcomes (p = 0.04). Only 7.9% were fully vaccinated. Almost half (46.1%) were intubated and mechanically ventilated. Patients spent an average of 12.1 days ventilated (SD:8.5), with an average of 6.0 days from admission to ventilation (SD:5.1). The intermediate group had a shorter average interval from admission to ventilator (77.2 hours, SD:67.6), than the poor group (212.8 hours, SD:126.8); (p = 0.001). The presence of bacterial pneumonia was greatest in the intermediate group (72.2%), compared to the favorable group (17.4%), and the poor group (56%); this was significant (p<0.0001). In-hospital mortality was seen in 28.1%. Conclusion: Most patients were male, obese, had moderate-level comorbidity, a history of tobacco abuse, and government-funded insurance. Nearly 50% required mechanical ventilation, and about 28% died during hospitalization. Bacterial pneumonia was most prevalent in intubated groups. Patients who were intubated with a good outcome were intubated earlier during their hospital course, with an average difference of 135.6 hours. A history of cigarette smoking and chronic lung disease were associated with poor outcomes.

Correction: Severe COVID-19 infection: An institutional review and literature overview

Corrigendum To: Genomic Diversity of Severe Acute Respiratory Syndrome–Coronavirus 2 in Patients with Coronavirus Disease 2019

Correction: Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review

Correction to: Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach

Author Correction: Prevalence and Characteristics of Hypoxic Hepatitis in the Largest Single-Centre Cohort of Avian Influenza A(H7N9) Virus-Infected Patients with Severe Liver Impairment in the Intensive Care Unit

Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747]

Erratum to: Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution (Journal of Zhejiang University-SCIENCE B, (2020), 21, 5, (408-410), 10.1631/jzus.B2000117)

Corrigendum: A Comparison of COVID-19 Stigma and AIDS Stigma During the COVID-19 Pandemic: A Cross-Sectional Study in China

Erratum To: Transmission Risk of Patients with COVID-19 Meeting Discharge Criteria Should Be Interpreted with Caution

Erratum: Author Correction: Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients

Correction to “In-hospital mortality and severe outcomes after hospital discharge due to COVID-19: A prospective multicenter study from Brazil” [Lancet Reg Health Am. 2022 Jul; 11:100244] DOI: 10.1016/j.lana.2022.100244

Erratum: Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum

Corrigendum: Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID

Correction to: Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals

Correction: Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study

Correction: Research disruption during PhD studies and its impact on mental health: Implications for research and university policy

Corrigendum: Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19

Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia

Corrigendum: Placental SARS-CoV-2 Infection and Its Implications for Increased Risk of Adverse Pregnancy Outcomes

Severe COVID-19 infection: An institutional review and literature overview

Correction: Silva Julian et al. Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era. Viruses 2024, 16, 1025